Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Estrogen | 13 | 2019 | 145 | 2.900 |
Why?
|
| Breast Neoplasms | 20 | 2022 | 1426 | 2.580 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2018 | 82 | 2.390 |
Why?
|
| Lung Neoplasms | 11 | 2018 | 336 | 2.090 |
Why?
|
| Receptors, Progesterone | 5 | 2021 | 78 | 1.920 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2019 | 31 | 1.610 |
Why?
|
| Signal Transduction | 16 | 2021 | 1802 | 1.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 178 | 1.450 |
Why?
|
| Estrogen Receptor beta | 4 | 2015 | 37 | 1.440 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2017 | 22 | 1.160 |
Why?
|
| Estrogens | 7 | 2022 | 190 | 1.050 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2023 | 5 | 0.940 |
Why?
|
| Cell Membrane | 5 | 2017 | 360 | 0.910 |
Why?
|
| Aromatase | 5 | 2011 | 19 | 0.880 |
Why?
|
| Estrogen Receptor Modulators | 5 | 2013 | 18 | 0.870 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2019 | 157 | 0.840 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 756 | 0.810 |
Why?
|
| Mammary Glands, Human | 1 | 2021 | 39 | 0.760 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 209 | 0.740 |
Why?
|
| Estradiol | 6 | 2023 | 244 | 0.730 |
Why?
|
| Estrogen Antagonists | 1 | 2019 | 26 | 0.710 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 56 | 0.670 |
Why?
|
| Cell Line, Tumor | 13 | 2019 | 2128 | 0.650 |
Why?
|
| Pyrazoles | 2 | 2017 | 80 | 0.650 |
Why?
|
| Phenylthiohydantoin | 1 | 2017 | 2 | 0.640 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 19 | 0.640 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2017 | 23 | 0.630 |
Why?
|
| Triazines | 1 | 2017 | 19 | 0.630 |
Why?
|
| Neoplasms | 2 | 2023 | 1033 | 0.620 |
Why?
|
| Cell Proliferation | 7 | 2019 | 1149 | 0.620 |
Why?
|
| Pyrroles | 1 | 2017 | 54 | 0.620 |
Why?
|
| Female | 29 | 2022 | 19873 | 0.600 |
Why?
|
| Pyrimidines | 1 | 2017 | 112 | 0.590 |
Why?
|
| Humans | 39 | 2023 | 34853 | 0.590 |
Why?
|
| Somatomedins | 1 | 2015 | 4 | 0.530 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 781 | 0.510 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 203 | 0.460 |
Why?
|
| Receptor, erbB-2 | 5 | 2019 | 122 | 0.450 |
Why?
|
| Aromatase Inhibitors | 4 | 2007 | 15 | 0.440 |
Why?
|
| Mice, Nude | 7 | 2019 | 323 | 0.430 |
Why?
|
| Nitriles | 2 | 2017 | 66 | 0.430 |
Why?
|
| Cell Nucleus | 3 | 2011 | 351 | 0.410 |
Why?
|
| Membrane Proteins | 2 | 2017 | 486 | 0.360 |
Why?
|
| Mice | 10 | 2019 | 5668 | 0.350 |
Why?
|
| Animals | 14 | 2019 | 14307 | 0.320 |
Why?
|
| Breast | 2 | 2021 | 134 | 0.320 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 184 | 0.320 |
Why?
|
| Estrogen Receptor alpha | 3 | 2007 | 105 | 0.320 |
Why?
|
| Hormones | 2 | 2005 | 51 | 0.320 |
Why?
|
| Steroids | 2 | 2005 | 43 | 0.310 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 16 | 0.290 |
Why?
|
| Membrane Microdomains | 1 | 2006 | 46 | 0.280 |
Why?
|
| Growth Substances | 1 | 2005 | 16 | 0.270 |
Why?
|
| Triazoles | 1 | 2005 | 85 | 0.260 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 69 | 0.260 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 211 | 0.250 |
Why?
|
| Neutrophils | 1 | 2023 | 124 | 0.220 |
Why?
|
| Progesterone | 1 | 2022 | 117 | 0.220 |
Why?
|
| Androgens | 2 | 2022 | 87 | 0.200 |
Why?
|
| Phosphorylation | 2 | 2019 | 878 | 0.190 |
Why?
|
| Cell Survival | 3 | 2017 | 818 | 0.190 |
Why?
|
| Transplantation, Heterologous | 4 | 2009 | 87 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 17 | 0.180 |
Why?
|
| Survival Analysis | 2 | 2018 | 322 | 0.180 |
Why?
|
| Cholestanols | 1 | 2019 | 2 | 0.180 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2019 | 18 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2019 | 91 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 242 | 0.160 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 46 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 269 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 649 | 0.150 |
Why?
|
| Benzamides | 1 | 2017 | 76 | 0.150 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 550 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 30 | 0.140 |
Why?
|
| Warfarin | 1 | 2016 | 59 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2016 | 97 | 0.140 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2015 | 1 | 0.140 |
Why?
|
| Cytokines | 1 | 2019 | 569 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 183 | 0.130 |
Why?
|
| Prognosis | 2 | 2015 | 707 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 605 | 0.120 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1349 | 0.120 |
Why?
|
| Epidermal Growth Factor | 2 | 2016 | 63 | 0.120 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 135 | 0.120 |
Why?
|
| Quinazolines | 1 | 2013 | 31 | 0.110 |
Why?
|
| Male | 6 | 2018 | 18870 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 2 | 2011 | 74 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 859 | 0.110 |
Why?
|
| Aged | 4 | 2018 | 6448 | 0.110 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 14 | 0.100 |
Why?
|
| Umbilical Cord | 1 | 2011 | 13 | 0.100 |
Why?
|
| Progestins | 1 | 2011 | 14 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 44 | 0.100 |
Why?
|
| Mifepristone | 1 | 2011 | 33 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 114 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2011 | 143 | 0.100 |
Why?
|
| Cell Division | 2 | 2009 | 296 | 0.100 |
Why?
|
| Middle Aged | 5 | 2018 | 9642 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2011 | 116 | 0.100 |
Why?
|
| Glycoproteins | 1 | 2011 | 100 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 229 | 0.090 |
Why?
|
| Peptides | 1 | 2011 | 308 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 97 | 0.080 |
Why?
|
| Endoplasmic Reticulum | 2 | 2005 | 101 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 94 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2011 | 296 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 445 | 0.080 |
Why?
|
| Transfection | 2 | 2005 | 496 | 0.070 |
Why?
|
| Disease Progression | 1 | 2009 | 580 | 0.070 |
Why?
|
| Protein Transport | 1 | 2007 | 286 | 0.070 |
Why?
|
| Dideoxynucleosides | 1 | 2006 | 11 | 0.070 |
Why?
|
| Receptors, Growth Factor | 1 | 2006 | 13 | 0.070 |
Why?
|
| Androstenedione | 1 | 2005 | 16 | 0.070 |
Why?
|
| Fluorine Radioisotopes | 1 | 2006 | 11 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 142 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2006 | 61 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 105 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 124 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2005 | 104 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2005 | 170 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 55 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2005 | 19 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2005 | 38 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 54 | 0.070 |
Why?
|
| Models, Biological | 2 | 2005 | 642 | 0.070 |
Why?
|
| Receptors, Steroid | 1 | 2005 | 33 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 72 | 0.070 |
Why?
|
| Cytosol | 1 | 2005 | 85 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2005 | 154 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 168 | 0.060 |
Why?
|
| Vinblastine | 1 | 2004 | 9 | 0.060 |
Why?
|
| Cysteine | 1 | 2005 | 88 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2004 | 21 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 52 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 240 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 121 | 0.060 |
Why?
|
| RNA | 1 | 2006 | 234 | 0.060 |
Why?
|
| Mitochondria | 1 | 2007 | 454 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2006 | 250 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 182 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 122 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2005 | 287 | 0.060 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2022 | 34 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 282 | 0.050 |
Why?
|
| Gene Expression | 1 | 2005 | 639 | 0.050 |
Why?
|
| Protein Binding | 1 | 2005 | 913 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2006 | 1442 | 0.050 |
Why?
|
| DNA Repair | 1 | 2022 | 181 | 0.050 |
Why?
|
| Mutation | 1 | 2006 | 1023 | 0.050 |
Why?
|
| Smoking | 3 | 2015 | 903 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2013 | 171 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 424 | 0.040 |
Why?
|
| Thiosemicarbazones | 1 | 2017 | 10 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 24 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 114 | 0.040 |
Why?
|
| Vitamin K | 1 | 2016 | 6 | 0.040 |
Why?
|
| Angiography | 1 | 2016 | 15 | 0.040 |
Why?
|
| Dyspnea | 1 | 2016 | 15 | 0.040 |
Why?
|
| beta Catenin | 1 | 2017 | 46 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2016 | 65 | 0.040 |
Why?
|
| Chest Pain | 1 | 2016 | 36 | 0.040 |
Why?
|
| Proline-Rich Protein Domains | 1 | 2016 | 7 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2016 | 212 | 0.040 |
Why?
|
| Cell Growth Processes | 1 | 2016 | 41 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 32 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 310 | 0.030 |
Why?
|
| Apoptosis | 2 | 2013 | 1317 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 117 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 859 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 480 | 0.030 |
Why?
|
| Adult | 3 | 2016 | 11034 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2011 | 61 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 834 | 0.020 |
Why?
|
| Beverages | 1 | 2006 | 64 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2006 | 79 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 79 | 0.020 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 3 | 0.020 |
Why?
|
| COS Cells | 1 | 2005 | 62 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2005 | 87 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 132 | 0.020 |
Why?
|
| Epirubicin | 1 | 2004 | 1 | 0.020 |
Why?
|
| Floxuridine | 1 | 2004 | 3 | 0.020 |
Why?
|
| Carboplatin | 1 | 2004 | 13 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2004 | 21 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2004 | 28 | 0.020 |
Why?
|
| Taxoids | 1 | 2004 | 36 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2004 | 48 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 86 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2004 | 80 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 485 | 0.010 |
Why?
|
| Nerve Tissue | 1 | 2003 | 7 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 597 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 964 | 0.010 |
Why?
|
| Ions | 1 | 2003 | 61 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2003 | 30 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 229 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 549 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 490 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 1353 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 1289 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 1300 | 0.010 |
Why?
|